Introduction
Finasteride is a 5α-reductase type II inhibitor and it is used in the treatment of benign prostatic hyperplasia and male pattern baldness (Drake et al., 1999 , Rittmaster et al., 1989 . In the Prostate Cancer Prevention Trial finasteride was proven to prevent or delay the development of prostate cancer, but the patients who developed cancer had a higher risk to develop a more aggressive form (Thompson et al., 2003) . 5α-reductase inhibition for prostate cancer prevention has been evaluated (Kramer et al., 2009) and recently it was shown that dutasteride, another 5α-reductase inhibitor, had an effect on the risk reduction for development of prostate cancer (Andriole et al., 2010) . For a drug that possibly will be used in a broad population for prevention of a disease it is always valuable to have as much information as possible of its pharmacokinetics (PK) and metabolism. In two recent publications we have investigated the plasma, biliary and urinary PK with a particular focus on the phase I, but also phase II metabolism of finasteride (Lundahl et al., 2009a , Lundahl et al., 2009b .
Finasteride is a CYP3A4 substrate in humans and it undergoes sequential phase I metabolism to ω -hydroxy finasteride (M1), finasteride ω-al (M2) and finasteride-ω-acid (M3) (Huskey et al., 1995) (Fig. 1) . It is completely metabolized in vivo, and biliary excretion was suggested to be the major elimination route for the metabolites formed (Carlin et al., 1992 , Carlin et al., 1997 . In previous reports, M1 was described as the major plasma metabolite and M3 as the major urinary metabolite in humans (Carlin et al., 1992) . Surprisingly, M1 was not present in quantifiable concentrations in the healthy volunteers administered finasteride before and after St. John's wort treatment, either in the normal or in the induced state (Lundahl et al., 2009a) . Instead, two other OH metabolites were isolated in human bile and urine (Lundahl et al., 2009b) . Finasteride can be classified as a biopharmaceutical classification system (BCS) class I compound (Amidon et al., 1995) . It has a high oral This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 11, 2011 as DOI: 10.1124 at ASPET Journals on October 20, 2017 dmd.aspetjournals.org Downloaded from DMD#035311 bioavailability (F=0.8) and therefore an expected high fraction absorbed (fa>85%) (Steiner, 1996) . Finasteride has a low aqueous solubility (0.04 mg/ml), but it will be classified as a highly soluble drug, because the low clinical dose of 5 mg is expected to be dissolved in 250 ml of water (Loftsson and Hreinsdottir, 2006) . According to the biopharmaceutical drug disposition classification system (BDDCS) it will also be classified as a class I compound with high solubility and extensive metabolism (Wu and Benet, 2005) .
Even though finasteride has been on the market for almost two decades there have only been a few reports that examine its involvement in drug-drug interactions (DDIs) (Winchell et al., 1993, Sudduth and Koronkowski, 1993) . In this investigation, we followed up the clinical metabolism interaction study (Lundahl et al., 2009a) as there is a need to improve the understanding of the in vivo PK of finasteride and its metabolites. In an earlier series of experiments conducted by colleagues in this research group, an advanced pig model has been applied ( Fig. 2 ). The pig model enables sampling from the portal vein (VP), the hepatic vein (VH), the femoral vein (VF) and bile collection directly from the biliary duct. This has made it possible to perform in depth investigations on the effects of several DDIs on intestinal absorption, intestinal metabolism, liver metabolism and hepatobiliary disposition (Petri et al., 2006 , Sjödin et al., 2008 , Bergman et al., 2009 , Thörn et al., 2009 . In this study, the model was used to in detail examine the effects of ketoconazole-inhibited cytochrome P450 (CYP) 3A mediated metabolism on the PK of finasteride.
The overall aim was to improve the understanding of the in vivo PK for finasteride and its metabolites M1 and M3. The specific aims were; first, to follow the plasma PK in three plasma sites (VP, VH and VF) and to study the consequences of ketoconazole-inhibited CYP3A mediated metabolism on the plasma profiles for finasteride and the metabolites.
Second, to study the biliary and urinary excretion of finasteride and its metabolites and the consequences of ketoconazole co-administration. Third, to compare the intravenous (iv) to the This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 11, 2011 as DOI: 10.1124 at ASPET Journals on October 20, 2017 dmd.aspetjournals.org Downloaded from DMD#035311 6 intrajejunal (ij) administration of finasteride to study the rate and extent of intestinal absorption and the effects of ketoconazole co-administration on the intestinal absorption.
Fourth, to compare the concentrations entering (VP) and leaving (VH) the liver to calculate the liver extraction ratio over time and follow the effects of ketoconazole inhibited CYP3A mediated metabolism in the liver. Fifth: to apply a semi-physiologically based PK model to the plasma data in the VP and VF to be able to study the effects of changes in specific PK parameters.
This article has not been copyedited and formatted. The final version may differ from this version. Janssen-Cilag (Buckinghamshire, UK). Solvents and other reagents were of analytical reagent grade and were purchased from Merck (Darmstadt, Germany). The water was purified using a Milli-Q water purification system (Millipore, Bedford, MA, USA).
Animals and study design. The investigation was approved by the local ethics committee for animal research in Uppsala, Sweden and it included 13 castrated male pigs, 10-12 weeks, of mixed breed (Hampshire, Yorkshire and Swedish Landrace). The pigs were randomized to three groups (Table 1) . A pilot study was performed for T1 and T2 on two animals, ID1 and ID2. All samples in the pilot study were analyzed and PK data analyses performed before continuing with the experiment by including the remaining animals. The results from the pilot study have been included in the data analyses presented below.
Investigational drugs.
Finasteride was administered in solution in all treatment groups. The ij dose (0.8 mg/kg) was dissolved in water containing 1% propylene glycol/ethanol 70/30 (v/v) and infused into the jejunum through a catheter (1.5 mm, diameter). The time taken to deliver the drug was 4.0-4.5 minutes. In T2, ketoconazole was administered at the same administration site 20 minutes prior to the finasteride dose. One ketoconazole tablet, 200 mg, was suspended in 5 ml 0.1 M HCl and, to obtain the correct dose for each animal (10 mg/kg), the dose was adjusted with a ketoconazole dispersion (20 mg/ml) depending on the weight of each pig. The time taken to deliver the ketoconazole was less than two minutes. For the iv administration (0.2 mg/kg), finasteride was dissolved in a total volume of 5 ml containing Anesthesia and surgical procedures. The pigs were anesthetized and surgery was performed according to previously described methods (Petri et al., 2006 , Sjödin et al., 2008 , Bergman et al., 2009 ). The body temperature, blood gases, blood pH, hematocrit, arterial and central venous pressures, heart rate and electrocardiographic parameters were continuously monitored during the entire experiment. The pigs underwent a tracheotomy and the oxygen pressure was controlled by mechanical ventilation with a Servo 900C ventilator (SiemensElema, Solna, Sweden). Catheters were inserted into an ear vein, the right VF, the central vein, the VH, the VP, the bile duct, small intestine and the urine bladder. The VH catheter was inserted through the jugular vein and its position controlled by fluoroscopy. To open the abdominal cavity, a midline incision was made enabling cannulation of the VP, the bile duct and small intestine. The surgical procedures and preparations proceeded for 90-120 minutes and, before administration of the investigational drugs, the animals were allowed to stabilize for 20-25 minutes. After 360 minutes of sampling the pigs received an iv injection of 20-30 mmol potassium chloride and this terminated the experiment.
Sampling of bile, urine and plasma. Blood samples were collected into lithium heparinized BD Vacutainers® (3 ml) (BD Biosciences, Franklin Lakes, NJ, USA) pre-dose and 10, 20, 30, 40, 50, 60, 90, 135, 180, 240 , 300 and 360 minutes after giving the ij dose, and 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 135, 150, 180, 240 , 300 and 360 minutes after injecting the iv dose.
The blood samples were centrifuged at 2350 g for 10 minutes (4°C) and the plasma separated.
To determine the blood to plasma ratio, extra blood samples were withdrawn from the VF after 30 and 300 minutes and diluted with water (1:3, v/v). Bile was continuously sampled on ice at 30-minute intervals from 0-360 minutes. Urine sampling was performed in 120-minute HPLC-UV analysis of finasteride in plasma and blood. Blood and plasma withdrawn at 30 and 300 minutes from the VF were used to determine the blood/plasma (C b /C p ) ratio and the fraction unbound (C u /C p ). To measure the unbound finasteride concentration (Cu), the plasma was centrifuged (40 minutes at 10,000 g) with Amicon ® Ultra centrifugal filters (0.5 ml, 10 K). Non-specific binding to the filter device was measured by centrifugation of an aqueous solution of finasteride. The total plasma concentrations (C p ) and blood concentrations (C b )
were determined. Five hundred microliters of plasma/blood were precipitated with 500 µl of acetonitrile and centrifuged (10,000 g, 10 minutes). After dilution with water the samples were loaded to Oasis®HLB 3cc columns. Following a column wash with water, the analytes were eluted from the columns with methanol/acetonitrile (v/v 1:1) that, then, was evaporated under a steam of nitrogen while heating the samples to 50°C. The analytes were dissolved in 150 µl mobile phase containing the internal standard, testosterone, and 100 µl was injected to the HPLC-UV system that consisted of a Shimadzu pump LC-10AD, a Waters 717 plus
Autosampler, a Spectra 100 UV detector (λ=210 nm) (Thermo Separation Products) and a C-18 Hypersil TM Gold column, 250 x 4.6 mm (5 μ m) (Thermo Scientific, UK) with a guard column. The isocratic mobile phase consisted of 60% 20 mM ammoniumacetate, 40% acetonitrile and 0.1% trifluoroacetic acid and was delivered at a flow of 1 ml/min. The linear concentration range used for the calibration curve was 0.003-1 µM.
HPLC-UV analysis of ketoconazole in plasma.
The analysis of ketoconazole in plasma from the VP and the VF was performed according to a previously described method (Vertzoni et al., 2006) . One hundred microliters of plasma was precipitated with 100 µl of acetonitrile containing the internal standard (9-acetylanthracene), centrifuged (10,000 g, 10 minutes) and 100 µl of the supernatant was directly injected into the HPLC-UV (λ=240 nm) system, described above. The mobile phase consisted of 70% methanol, 29% water and 1% diethylamine and was isocratically delivered at a flow of 1 ml/min. The linear concentration range used for the calibration curve was 0.04-50 µM.
PK data analysis. The PK parameters were calculated from the plasma and bile non-compartment analyses (NCA), the AUC was estimated using the linear trapezoidal method for ascending values and the log trapezoidal method for descending values. The AUC 0-6 h was calculated from time zero until the last measured concentration point (C last ).
AUC 0-∞ was calculated by extrapolating the curve to infinity by adding C last /λ z to AUC 0-6 h , where λ z is the first-order terminal disposition rate constant. C max and the time taken to reach C max (t max ) were obtained directly from the plasma concentration-time profiles. Concentrations below the lower limit of quantification before C max were set to zero, and were otherwise (after C max ) excluded from the calculations. The terminal half-life (t 1/2 ) was calculated as ln2/λ z .
Following the iv administration, the apparent volume of the distribution in the steady state (V ss ) was calculated as MRT*CL, where the mean residence time (MRT) was calculated as the area under the first moment curve (AUMC 0-6h ) divided by AUC 0-6h . The total CL following iv administration was calculated as:
Since the hepatic clearance (CL H ) was assumed to be equal to the total CL after iv administration, E H was calculated as:
with a liver blood flow (Q H ) in pig of 52 ml/min/kg (Nordgren et al. 2002) and where C b /C p is the measured blood/plasma ratio for finasteride in pig. In all three of the groups given different treatments, E H could also be calculated by comparing the plasma concentrations in the VP and the VH at each time point, or by using partial AUCs or the AUC 0-6 h .
CL H could also be calculated from E H (from equation 3), by rearranging equation 2. The oral bioavailability in T1 and T2 was calculated as:
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where AUC VF,IV was an average AUC (n=3). The fraction of the dose excreted into bile (f bile )
during the 6 hours of sampling was determined from the total amount of finasteride or M3 excreted into bile divided by the ij/iv dose. The fraction of the dose excreted into urine (f urine )
during the 6 hours of sampling was calculated as the total amount of finasteride or M3 excreted into urine divided by the ij/iv dose. The apparent biliary clearance was calculated by comparing the amount of finasteride/M3 excreted to the bile with the AUC VP
and the renal clearance was calculated with the following equation.
For the one-and two-compartment analyses, WinNonlin models were used. Model 8 (bolus input, first-order output) was used for the two-compartment modelling of the iv data and C1, 4 (first-order input, first-order output and lag-time) was used for the one-compartment modelling of the ij data and the absorption rate (k 01 ) and the elimination rate (k 10 ) constants were estimated. The CV% of the estimated parameters, total statistics for the models and curve fits were compared to evaluate the models.
Deconvolution of data was performed using WinNonlin software. The response function, r(t), was derived from the concentration-time profiles for the VP and VF following T1 and T2. The weight function, w(t), was derived from the two-compartment analyses of the concentration-time profiles in the VP and the VF following iv administration. C1 and C2 were multiplied by a factor of four to compensate for the four times lower iv dose than the ij dose (Table 1 ). The input function, i(t) was derived from deconvolution: i(t)=r(t)//w(t). The initial rate was set to zero, automatic smoothing was used and the number of output data terms to be calculated was set to 101.
Semi-physiological PK model for finasteride. The PK of finasteride in the VP and the VF after ij administration, for T1 and T2, were described by a semi-physiological PK model comprised of compartments for the gut wall, the portal vein, the liver the central vein, and the peripheral distribution compartment. The model is described in detail in the Appendix. It was built in Berkley Madonna version 8.3 (University of California, CA, USA) and was derived through the combination of previously described models presented by (Fang et al., 2000 , Yang et al., 2003 , Zhang et al., 2009 , Rowland Yeo et al., 2010 Statistics. Unpaired, two-sided Student's t-tests were performed in order to evaluate the differences between the treatments. For t max , the two-sample Mann-Whitney test was used.
Differences were considered to be statistically significant when p<0.05. It was determined that five animals in each group were required to detect a two-fold difference in the plasma AUC with 80% power (α=0.05). This calculation was based on results obtained from the pilot study and an assumed large standard deviation. All data was included in the statistical analysis for all parameters, except t 1/2 . For this parameter, outlier tests were performed using a general linear model and the software Minitab 15.1 (Minitab Inc., Pennsylvania, PA, USA), to calculate the deleted studentized residuals (the residual divided by the standard deviation of the residual minus one observation) and Cook's distances. A value was excluded from the data analysis if it had a deleted studentized residual of greater than 2.0 and an unusual value for Cook's distance; the comparisons were made for the latter by composing a graph of distances versus observations (time series plot).
Results
This report includes data for finasteride and M3 in plasma (VP, VH and VF) and in bile and three groups of treatment. The AUC 0-6 h (from NCA) was used for all calculations (equations 1-7), because the extrapolated areas for AUC 0-∞ (NCA) were considered to be too large (>25%) to be used with confidence. However, the AUC 0-6 h (NCA) was not significantly different from those obtained with the AUC 0-∞ (NCA) or from the one-or two-compartment analysis.
Plasma PK, biliary and urinary excretion of finasteride and M3 after intravenous administration. In the iv group, the plasma concentration-time profiles for finasteride in the VP and the VF were well described by a two-compartment PK model (Fig. 3A , Table 2 ).
These data were used for the deconvolution and the semi-physiological model. For VH, the profile (after iv administration) was not well described by a compartment PK model. In the iv group, the CL and E H for finasteride were low (Table 3 ). The presence of M3 in the plasma (VF) was low compared to the presence of finasteride indicated by an AUC VF, 0-6 h ratio (M3/finasteride) of 0.12 (range 0.08-0.13) ( Table 3) . M3 was continuously formed during the 6 hours of the experiment and, therefore, the estimations of C max , t max and t 1/2 were uncertain (Fig. 3A) . In the iv group, a low amount of unchanged finasteride was excreted to bile and urine during the 6 hour-long experiment (Table 4 and 5). M3 was excreted into both bile and urine after iv administration, but with a large inter-individual variation (see Tables 4 and 5 ).
The effect of ketoconazole on the plasma exposure of finasteride and M3, after intrajejunal administration (T1 and T2). The plasma exposure (AUCs) of finasteride was increased, (p<0.05) and the plasma exposure of M3 was decreased (p<0.05) at all three sampling sites in T2 (Fig. 3B-3D , Table 6 ). Ketoconazole increased the bioavailability and prolonged the t 1/2 for finasteride (Table 3 and 6). The AUC VF, 0-6 h ratio (M3/finasteride) decreased from 1.4 (range 0.13-4.1) to 0.06 (range 0.04-0.09) for T1 and T2, respectively (Table 3 ). There was a large inter-individual variation in the plasma concentration-time profiles in the T1 group (Fig. 3E) , which was reduced in the T2 group (Fig. 3F) The apparent absorption kinetics of finasteride from the gut lumen to the VP and the VF were investigated both by one-compartment analysis (k 01 ) of the concentration-time profiles and by deconvolution (k a , t 1/2, abs ) of the ij data to iv data ( Fig. 4 and Table 6 ). The absorption half-life (t 1/2,abs ), obtained from deconvolution, from the intestine to the VP was short and there was an increased t 1/2,abs with ketoconazole co-administration from 2±1 to 4±2 minutes (p<0.05), for T1 and T2, respectively. From the intestine to the VP the cumulative input fraction was derived from deconvolution and this represents both the fractions of the dose absorbed and the fraction that escapes gut wall metabolism (fa*F G ). This fraction (fa*F G ) was close to one (i.e. 100%) in T1 and this was not significantly affected by ketoconazole in T2
( Fig. 4A and 4C ). The absorption to VP started immediately after both T1 and T2 without any lag-time in six animals and with a delay ranging from 1-9 minutes in four animals. The apparent absorption rate constant (k a ), derived from deconvolution, from the intestine to the VF was lower (p<0.05 in T1 and T2) compared to the k a to the VP (Fig. 4B , Table 6 ). In addition, for the absorption to the VF there was a lag-time of 13±4 and 10±1 minutes for T1
and T2, respectively. It was concluded that the input rate to the VF was significantly affected by the distribution and that the input rate to the VP better described the intestinal absorption kinetics. The cumulative input fraction, (Fig. 4D) , from the intestine to the VF represents the bioavailability (F) and this was significantly (p<0.05) increased by ketoconazole (Table 3) .
By calculating E H with equation 4 for each time point, or using equation 3 with the partial AUCs for 0-1 h, 1-2 h etc., it was found that E H varied over time (Fig. 5) 
The effect of ketoconazole on the biliary and urinary excretion of finasteride and M3
after intrajejunal administration (T1 and T2). In total, in both groups, the fraction of the dose excreted to bile and urine as unchanged finasteride during the 6 hour-long experiment was ≤ 0.4% of the amount administered (Tables 4 and 5 ). However, in T2, there was a tendency towards increased biliary excretion of finasteride (Fig. 6A ) and the amount of finasteride excreted to urine was significantly (p<0.05) increased (Fig. 6C ). The interindividual variation in the amount of excreted M3 to bile (Fig. 6B ) and urine ( Fig. 6D ) was large, and no statistically significant difference between T1 and T2 could be determined. M3
was probably actively excreted to bile against a concentration gradient and the AUC ratios (bile/plasma) of the total concentrations were 100 times higher in bile (Table 4 ). This ratio was not affected by ketoconazole co-administration. The AUC bile /AUC VP ratio for finasteride was close to 1 in T1 and this indicated that finasteride was excreted to bile by passive diffusion.
Blood/plasma ratio and fraction unbound of finasteride. The ratio C b /C p was determined in two individuals (ID4 and ID13) from samples withdrawn at 30 and 300 minutes and was determined to be 1.03±0.23. The hematocrit was 27±3%, (n=36, 10 animals). The fraction unbound for finasteride in pig plasma was 0.17±0.15 (n=5, 3 animals).
This article has not been copyedited and formatted. The final version may differ from this version. Ketoconazole PK in plasma (T2). The ij administration of ketoconazole resulted in a C max of 9±3 µM in the VP and of 3±1 µM in the VF. See the plasma PK data for ketoconazole in the VP and VF in Table 7 .
Semi-physiological PK model. A semi-physiological PK model could describe the observed data in VP and VF for T1 and T2 (Fig. 7A-7D) . Firstly, a model that described the mean plasma concentration-time curves in the VP and the VF for the control group, T1, was developed. The following parameters were found to be of importance and were adjusted to improve the correspondence of the observed mean and the model concentration-time curves;
V pv , k gl , k pv , Q h , V maxgw , K m , V max and fa (Table 8) . Secondly, for the description of the mean curves for T2, the measured ketoconazole C max values in the VP and the VF were added as the inhibitor concentration in the gut wall and liver, and values of K i and fu for ketoconazole, obtained from the literature, were included, see Appendix and Table 8 for detailed information. When these data were added to the model, the interaction was not completely described. After increasing the inhibitor concentration in the liver, the interaction was better described. Variations in the gut wall inhibitor concentration did not have a significant effect on the plasma concentration-time profiles. All parameters were kept as for T1 (Table 8) except for the volume of the central venous compartment (V cent ) (see equation 1, Appendix) that had to be somewhat decreased. The final model did give a fairly good description of the way in which the plasma concentration-time profiles of finasteride were affected by inhibition of the metabolism of finasteride in the gut wall and the liver (Fig. 7E-7F , Table 8 ).
Discussion
In this study, the effects of ketoconazole co-administration on the PK in three plasma compartments (VP, VH and VF), were examined along with the biliary and urinary excretion of finasteride and its metabolites. In addition, the intestinal absorption and the liver extraction ratio for finasteride were studied and the effects of ketoconazole co-administration examined.
The major findings were that ketoconazole co-administration caused an increased F and a prolonged t 1/2 for finasteride and a decreased plasma exposure (AUC and C max ) for M3.
Metabolism in the liver (CL H and E H ), and not the gut wall, was suggested to be of major importance for this DDI and this is further discussed below. The sequential route of metabolism from finasteride to M3 was almost completely inhibited and the AUC VF, 0-6 h ratio (M3/finasteride) decreased. This confirmed that CYP3A is important for the plasma exposure of finasteride and for the sequential formation of M3. It was possible to build a semiphysiological PK model, including five compartments (the gut wall, portal vein, liver, peripheral vein and the central vein) to describe the plasma concentration-time profiles in the VP and the VF in T1 and to sufficiently describe the profiles in T2.
Finasteride was found to have a route-and time-dependent E H (Fig. 3 ) in pigs. The E H was intermediate, and almost high, the first hour after intrajejunal administration of the drug and this was when the concentrations of finasteride were high in the VP during the absorption and distribution phases. Ketoconazole had an effect on the E H , which decreased during the elimination phase from 1-6 hours. Finasteride has been reported to have a linear PK in humans (Ohtawa et al., 1991) , except when low doses (0.2 mg) were administered (Suzuki et al., 2010) . The finding of a higher value for E H at higher VP concentrations is unexpected and not easily explained. The same type of phenomena was found also for R-and S-verapamil when the gut wall metabolism was inhibited by ketoconazole and the AUC in the VP was increased (Thörn et al., 2009 higher VP concentrations and it was suggested to be the result of saturable plasma protein binding for R-and S-verapamil (Thörn et al., 2009) . A possible hypothesis for the finasteride observation could also be a temporary saturation of plasma protein binding that would increase the fu and thereby the CL H . An explanation for the finding that the metabolism in the liver does not seam to be saturated with the high incoming VP concentrations is that finasteride could distribute within the liver, possibly bind to the liver tissue components, and cause a "sink" in the liver which reduces the risk of saturating the metabolism (Rubin and Tozer, 1986) . Based on previous experiments and the careful monitoring of the physiological parameters of the animals in this laboratory the liver blood flow is expected to not vary over time and to be comparable between the pigs in the different groups (Nordgren et al., 2002) .
Worth to mention, the biliary excretion data of finasteride does not contribute to explain this finding. The observation that the k 01 and k a to the VF was lower compared to the k 01 and k a to the VP correlates to the theory that there is a mechanism, possibly binding and distribution within the liver that delays the absorption (input rate, h -1 ) to the VF and that takes place the first hour after ij administration of finasteride (Fig. 2 , Table 6 ).
It is an interesting observation that the input rate, indicated by k a and t max , into VF was lower than to the corresponding parameter to VP. In oral drug product development, it is of importance to establish in vitro-in vivo correlation (IVIVC) of drug absorption and this is always based on plasma concentration-time data from a peripheral vein. Therefore, the observation in this study that there exists a difference in the absorption rate constant (k a )
based on the plasma compartments in the VP and VF might be of importance for assessment of in vivo bioequivalence, especially C max and t max . It has the potential to explain why an in vitro-in vivo correlation is difficult to establish for some oral pharmaceutical products. (0.14 L/h/kg) (for a 70 kg individual) and 0.8 (Steiner, 1996) , respectively. The total plasma CL (L/h/kg) was three times higher in pigs compared to humans and V ss (L/kg) was almost identical. The F was lower in pigs compared to humans and there can be two explanations for this finding, either a difference in fa*F G or a difference in F H between humans and pigs. The most plausible explanation is that the F H is lower in pigs compared to humans as reflected by the three times higher total plasma CL (L/h/kg) in pigs. CYP3A4 has been identified as the major enzyme responsible for the sequential formation of M3 (Huskey et al., 1995) . In a recent report the most abundant CYP subfamilies in pigs were found to be CYP2A, 2D, 2C
and 3A and this was identified using MALDI TOF mass spectrometry (Achour et al., 2010) .
Four enzymes in the CYP3A family have been cloned from pigs (domestic and minipig) CYP3A22, CYP3A29 (Nissen et al., 1998) , CYP3A39 and CYP3A46 with 75-78% amino acid identity to human CYP3A4 and 82-84% nucleotide similarity (Sakuma et al., 2004) .
Enterocytes, hepatocytes, liver and intestinal microsomes from pigs have been used to study drug metabolism and, even though the CYP3A enzymes are not identical to CYP3A4, similar activity and a corresponding rate of metabolism have been observed for substrates such as testosterone and tacrolimus (Skaanild and Friis, 1997 , Bader et al., 2000 , Olsen et al., 1997 .
Inhibition of CYP3A mediated metabolism by ketoconazole has been reported in pig intestinal microsomes (Lampen et al., 1996) . In addition, in two previously reported pig studies ketoconazole inhibited the stereo-selective gut wall metabolism of the CYP3A4
substrates S-and R-verapamil (Thörn et al., 2009 ) and the metabolism of tacrolimus (Sano et al., 2002) . This study gives further evidence that the pig is a relevant model animal for CYP3A substrates.
The pigs were kept under anesthesia and the body temperature, blood pressure, blood pH and blood gases carefully monitored by an animal nurse during the experiment (Bergman et al., 2009 , Sjödin et al., 2008 , Petri et al., 2006 . The splanchnic blood flow has been This article has not been copyedited and formatted. The final version may differ from this version. monitored with indocyanine green measurements in pigs that were anesthetized with the same drugs and at the same laboratory (Nordgren et al., 2002) . The splanchnic blood flow was 51±7 ml/min/kg at the starting point and 49±4 ml/min/kg after 4 hours experiment. Seven different drug substances (Sjödin et al., 2008) were used in this study to cause the anesthesia and pain relief. Four of these drugs (ketamin, pancuronium, tiletamide and zolazepam) are known to be metabolized by CYP enzymes or to affect CYP mediated metabolism (Hijazi and Boulieu, 2002 , Nagashima et al., 2005 , Wong and Bandiera, 1998 . All pigs received identical anesthesia and analgesia in combination with the drugs under investigation and this makes it possible to compare the data between the groups.
Finasteride was excreted in its unchanged form to a minor extent into bile and urine (<0.4% in all treatment groups) in pigs, which was in agreement with the biliary and urinary excretion in humans (Lundahl et al., 2009a) . It was also in agreement with a previous clinical study when 57% and 39% of a [ 14 C]-labeled finasteride oral dose was excreted as metabolites to feces and urine, respectively (Carlin et al., 1992) . Unfortunately, M1 was detected, but not present in quantifiable concentrations. Instead of M1, two other OH metabolites were detected in urine and bile from the pigs (Lundahl et al., 2009b , Lundahl et al., 2010 . The novel data, from this pig study, indicate that, not only urinary excretion but also biliary excretion can be of importance for M3. The high (Table 4) AUC-ratio of M3 in bile/VP and bile/VH indicated that carrier-mediated transporter proteins are probably involved in transporting M3 from the hepatocytes to bile. The high bile/plasma ratio was in agreement with our human study when the bile/plasma AUC ratio was 30-fold. Biliary excretion of finasteride in pig was probably driven by diffusion with an AUC bile /AUC VP ratio close to 1 (Table 4) .
A first attempt to simultaneously investigate the plasma concentrations in two of the measured plasma compartments was made by building a semi-physiological PK model, which nicely described the plasma concentration-time curves in the VP and the VF following T1 and the extent of the DDI in T2. The DDI was first under-predicted when the measured C max for ketoconazole in the VP and the VF were used as the gut wall (I gw ) and liver (I liver ) inhibitor concentrations, respectively. Then, when the total inhibitor concentration in the liver was increased, from 3 to 6.5 µM, the DDI was better predicted (Fig. 7) . Increasing the inhibitor concentration in the gut wall was not found to be relevant for improving the prediction. To conclude, when using the semi-physiological PK model to describe the data, an inhibitor concentration in the liver between C max in VP and VF was found to be most relevant.
In conclusion, ketoconazole caused an increased F and prolonged the t 1/2 for finasteride and this was concluded to be the results of inhibited liver metabolism and reduced CL H and E H . The extent of transport of finasteride from the gut lumen to the VP was high already in the control group and not significantly affected by ketoconazole. This suggested a minor contribution of gut wall metabolism and a high intestinal permeability. Interestingly, it was found that the rate constant (k a ) to the VP was higher compared to the VF and this was possibly caused by binding or distribution within the liver. A semi-physiological based PK model was applied to describe the VP and the VF plasma concentration-time profiles in T1, and accurately described the effects of ketoconazole inhibition of the gut wall and liver metabolism in T2. The PK of finasteride in pig showed many similarities to the PK in humans and the data achieved in this study could and can be used to better understand the PK and DDIs for finasteride in humans.
This article has not been copyedited and formatted. The final version may differ from this version. (Carlin et al., 1992) . CYP3A4 has been identified as the major enzyme involved in the biotransformation of M1 and M3 (Huskey et al., 1995) . Zhang et al., 2009, c adjusted to improve the model in T1, d estimates from one-compartment analyses in T1, e Nordgren et al., 2002 , f measured in this study, g estimated from CL after iv administration and from Ishii et al., 1994 , h Steiner et al., 1996 
